Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline clinical characteristics of the study population (n = 89)
Characteristics 
Age (yr)^{^a} 57.8 (SD, 12.8)
Sex (male/female) 43:46
EGFR mutation–positive 41 (46.1)
MGMT promoter methylation–positive status 30 (33.7)
KPS at treatment initiation (%) 
 >70 75 (84.3)
 ≤70 14 (15.7)
Surgical extent (%) 
 Gross total resection 51 (57.3)
 Partial resection 28 (31.5)
 Biopsy 10 (11.2)
Maximal diameter (mm)^{^a} 44.9 (SD, 15.4)
Adjuvant treatment (%) 
 Standard CCRT+TMZ 82 (92.1)
 RT+TMZ 11 (12.4)
OS (months)^{^a} 17.7 (SD, 11.7)
Note:—CCRT indicates concurrent chemoradiation therapy; RT+TMZ, hypofractionated RT for elderly patients with a hypofractionated radiation schedule (40 Gy in 15 fractions for 3 weeks) with TMZ.
↵a Data are expressed as means.

Characteristics
Age (yr)^{^a}	57.8 (SD, 12.8)
Sex (male/female)	43:46
EGFR mutation–positive	41 (46.1)
MGMT promoter methylation–positive status	30 (33.7)
KPS at treatment initiation (%)
>70	75 (84.3)
≤70	14 (15.7)
Surgical extent (%)
Gross total resection	51 (57.3)
Partial resection	28 (31.5)
Biopsy	10 (11.2)
Maximal diameter (mm)^{^a}	44.9 (SD, 15.4)
Adjuvant treatment (%)
Standard CCRT+TMZ	82 (92.1)
RT+TMZ	11 (12.4)
OS (months)^{^a}	17.7 (SD, 11.7)